NYSE: USNAUsana Health Sciences Inc Stock
$27.89+0.35 (+1.27%)
Updated Apr 29, 2025
USNA Price
$27.89
Fair Value Price
N/A
Market Cap
$527.25M
52 Week Low
$23.10
52 Week High
$49.78
P/E
12.68x
P/B
0.99x
P/S
0.8x
PEG
0.84x
Dividend Yield
N/A
Revenue
$854.50M
Earnings
$42.03M
Gross Margin
81.1%
Operating Margin
8.96%
Profit Margin
4.9%
Debt to Equity
0.3
Operating Cash Flow
$61M
Beta
0.63
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
USNA Overview
USANA Health Sciences Incorporated manufactures nutritional and personal care products such as vitamin and mineral supplements, targeted supplements designed to meet cardiovascular, skeletal/structural, and digestive health needs, and meal replacement shakes, snack bars, and related products. USANA was founded in 1992 and is headquartered in Salt Lake City, UT.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine USNA's potential to beat the market
BBuy
- Stocks with a Zen Rating of Buy (B) had an average return of +19.88% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Food
Industry Rating
B
USNA
Ranked#18 of 49
Ranked#18 of 49
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $12.35 | A | |
| $11.97 | A | |
| $7.07 | A |
Be the first to know about important USNA news, forecast changes, insider trades & much more!
USNA News
Overview
Due Diligence Score
–
Industry Average (29)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how USNA scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
USNA ($27.89) is trading above its intrinsic value of $24.15, according to an updated version of Benjamin Graham's Formula from Chapter 11 of "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
USNA is good value based on its earnings relative to its share price (12.68x), compared to the US market average (29.19x)
P/E vs Market Valuation
USNA is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
There are 30 more USNA due diligence checks available for Premium users.
Valuation
USNA price to earnings (PE)
For valuing profitable companies with steady earnings
Company
12.68x
Industry
15.85x
Market
29.19x
USNA is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
USNA is good value based... subscribe to Premium to read more.
P/E vs Market Valuation
USNA price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.99x
Industry
1.92x
USNA is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
USNA price to earnings growth (PEG)
For valuing profitable companies with growth potential
USNA is good value based... subscribe to Premium to read more.
PEG Value Valuation
USNA's financial health
Profit margin
Revenue
$213.6M
Net Income
$4.5M
Profit Margin
2.1%
USNA's Earnings (EBIT) of $76.60M... subscribe to Premium to read more.
Interest Coverage Financials
USNA's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$748.2M
Liabilities
$161.9M
Debt to equity
0.3
USNA's short-term assets ($279.19M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
USNA's short-term assets ($279.19M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
USNA's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
USNA's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$5.8M
Investing
-$205.1M
Financing
$22.9M
USNA's operating cash flow ($60.99M)... subscribe to Premium to read more.
Debt Coverage Financials
USNA vs Food Stocks
Usana Health Sciences Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.